XRpro Sciences, formerly Caldera Pharmaceuticals, is a Cambridge, MA-based provider of a platform for drug discovery and development services. Its XRpro technology enables high-throughput screening of ion channel assays and directly measures drug-target activity without the need for chemical dyes or radiolabels. The platform is offered to the pharmaceutical industry for ion channel screening. The company is led by President and CEO Richie Cunningham and Chairman Tim Tyson. XRpro completed an $8.855M equity financing and intends to use the proceeds to continue to grow operations. The funding is directed toward expanding the company's operations.

Total raised

$9M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2015